Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00328731
Other study ID # NAR Foundation study 120
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received May 19, 2006
Last updated May 19, 2006
Start date January 2005
Est. completion date January 2006

Study information

Verified date January 2005
Source Nambudripad's Allergy Research Foundation
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

We sought to determine the efficacy of NAET® in permanently eliminating milk allergy for a sample of patients.

We hypothesize that the subjects in the experimental group will show similar level of allergies and sensitivities initially on all nine diagnostic measures used here. After receiving the NAET treatments, the Experimental group will demonstrate a significant reduction in the milk sensitivities and allergies when compared to the control group at the final evaluation using same diagnostic measures.


Description:

Background: Although several standard clinical techniques are used to detect and treat common allergic conditions, each one is limited in scope and requires to follow repeated treatment protocols. The non-invasive system known as NAET® does not generally have such limitations and has over the last twenty-three years been demonstrated to be effective clinically in thousands of cases. NAET® is a natural treatment that utilizes standard medical diagnostic measures along with kinesiolgocal, chiropractic and oriental testing, procedures to identify the allergens, as well as the intensity of reactions to the allergens which vary from individual to individual. Treatment consists of a sequence of spinal manipulations at specific thoracic and lumbar spinal levels along with acupuncture acupressure on configurations of standard acupuncture points.

Methods: In a double blind study, 26 patients with diagnosed milk allergy (13 males, 13 females, age range between 18-65 years) were randomly assigned to 2 groups:

1. NAET®/Experimental group, and

2. Placebo/control group The study was conducted by 12 volunteer-clinicians from NAET Research associates, divided into six investigator groups. Each group conducted a designated sequential part of the study independently from all other groups, that is, was blinded from all other groups for the duration of the study. Subjects from both groups (Experimental and Control) were evaluated immediatedly before treatment and eight weeks thereafter using the following nine diagnostic measures: Subjective history (Allergy Symptom Rating Scale or ASRS); ALCAT Test; antibodies to milk protein in the blood serum by Immunoglobulins G, Immunoglobulins A, Immuno-globulins M, and Immunoglobulins E (IgG, IgA, IgM, IgE) by Elisa method (enzyme linked Immunozorbant Assay); Intradermal testing for milk sensitivity. NSTRS (Kinesiological muscle response testing also known as Neuromuscular Sensitivity Testing) and Pulse difference Rating Scale (PDRS) were tested by two well trained NST clinicians at two different times before and after the treatments. Both groups demonstrated allergic sensitivities to whole milk test sample in varying degrees. After completing the evaluations, the Experimental group received 2 NAET® treatments on whole milk, on two consecutive Saturdays. The Placebo group received two treatments on placebo samples on the same days along with the experimental group on two consecutive Saturdays as well. At the end of the treatment phase, once again both groups were evaluated for whole milk test sample using all of the nine diagnostic measures.

Results On the nine diagnostic measures there was a significant difference in the means of the before and after measures of the Experimental group, while they remained almost the same for the Placebo group. At 95% CI, p-values were less than 0.05 in all tests except for IgG study (p-value=1.30). NSTRS and PDRS were evaluated by two clinicians at different time to evaluate the intertester relability among two clinicians for these two tests. A significant correlation was noticed with the results both testers received on these two testing–NST and PDRS (p-value <0.0001).

Conclusion The study demonstrated the efficacy of eliminating or reducing milk allergy using the NAET® treatment protocol. This study also evaluated the reliability of performing two testing procedures (NST & PDRS) by two independent examiners in testing the subjects for milk at two different times. There was a significant correlation in the results they received as shown above, when the two clinicians tested the subjects independently, demonstrating that there is a good reliability between these well trained clinicians in their performance while doing these two evaluations.


Recruitment information / eligibility

Status Completed
Enrollment 26
Est. completion date January 2006
Est. primary completion date
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 78 Years
Eligibility Inclusion Criteria:

Known milk allergy, sensitivity or intolerances. -

Exclusion Criteria:

No milk allergy or sensitivity H/o Anaphylaxis or severe reactions Any other major illnesses preventing from taking part in any study

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Procedure:
Procedure


Locations

Country Name City State
United States NAET-Pain Clinic Buena park California

Sponsors (1)

Lead Sponsor Collaborator
Nambudripad's Allergy Research Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Reduction of Milk allergies
Secondary This study also evaluated the reliability of performing two testing procedures (NST & PDRS) by two independent examiners in testing the subjects for milk at two different times.
See also
  Status Clinical Trial Phase
Completed NCT01950533 - The Utility of Food-Specific IgE Measured With the IMMULITE 2000 Assay to Predict Symptomatic Food Allergy
Completed NCT02579876 - Milk Patch for Eosinophilic Esophagitis Phase 2
Completed NCT04318483 - Characteristic and Evolution of an Atypical IgE-mediated Cow Milk Allergy Form With Hands and Feet Angio-oedema
Completed NCT02317952 - Formula for Children With Cow's Milk Allergy N/A
Completed NCT00968110 - Xolair Treatment for Milk Allergic Children Early Phase 1
Recruiting NCT03309488 - Basophil Activation Test to Diagnose Food Allergy
Recruiting NCT05309772 - The Clinical Impact of the Basophil Activation Test to Diagnose Food Allergy N/A
Terminated NCT02719405 - Impact of Infant Formula on Resolution of Cow's Milk Allergy Phase 2
Completed NCT01361347 - Safety of Oral Immunotherapy for Cow's Milk Allergy in School-aged Children Phase 4
Completed NCT01157117 - OIT and Xolair® (Omalizumab) in Cow's Milk Allergy Phase 2
Active, not recruiting NCT00732654 - The Safety and Efficacy of Sublingual/Oral Immunotherapy for the Treatment of Milk Protein Allergy Phase 1/Phase 2
Recruiting NCT03819556 - Swedish Study of Immunotherapy for Milk Allergy in Children N/A